Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis

National Committee for Clinical Laboratory Standards

Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736

Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis

Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380

A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia

Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039

Resistance of Candida species to fluconazole

Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 880

Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients

Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors

Douglas, C. M., D'Ippolito, J. A., Shei, G.-J., Meinz, M., Onishi, J. C., Marrinan, J. A., Li, W., Abruzzo, G. K., Flattery, A. M., Bartizal, K. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2471 · Cited by 344

Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients

Wingard, J. R., Merz, W. G., Rinaldi, M. G., Miller, C. B., Karp, J. E., & Saral, R. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1847 · Cited by 339

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.451-457.2002 · Cited by 254

Fluconazole resistance in Candida glabrata

Hitchcock, C. A., Pye, G. W., Troke, P. F., Johnson, E. M., & Warnock, D. W. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1962 · Cited by 244

Compounds active against cell walls of medically important fungi

Hector, R. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.1.1 · Cited by 242

Emerging Complexity and the Need for Advanced Drug Delivery in Targeting Candida Species

Wadhwa, R., Pandey, P., Gupta, G., Aggarwal, T., Kumar, N., Mehta, M., Satija, S., Gulati, M., Madan, J., Dureja, H., et al. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191026105308 · Cited by 27

Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin

Maschmeyer, G., & Glasmacher, A. G. (2005) · Mycoses · doi:10.1111/j.1439-0507.2005.01131.x · Cited by 26

A Single‐Centre 10‐Year Experience with Candida Bloodstream Infections

Labbé, A., Pépin, J., Patiño, C., Castonguay, S., Restieri, C., & Laverdière, M. (2008) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2009/731070 · Cited by 25

Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates

Walraven, C. J., Bernardo, S. M., Wiederhold, N. P., & Lee, S. A. (2013) · Medical Mycology · doi:10.1093/mmy/myt007 · Cited by 24

The use of caspofungin in HIV-infected individuals

Waters, L. J., & Nelson, M. R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.899 · Cited by 23

Clinical characteristics of the first cases of invasive candidiasis in China due to pan-echinocandin-resistant Candida tropicalis and Candida glabrata isolates with delineation of their resistance mechanisms

Xiao, M., Fan, X., Hou, X., Chen, S. C.-J., Wang, H., Kong, F., Sun, Z., Chu, Y., & Xu, Y. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s152785 · Cited by 22

The antifungal activity of caspofungin in combination with antifungals or non-antifungals against Candida species in vitro and in clinical therapy

Su, S., Yan, H., Li, M., Wang, H., Chen, X., Shi, J., & Sun, S. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1941868 · Cited by 22

Susceptibility of Candida albicans to common and novel antifungal drugs, and relationship between the mating type locus and resistance, in Lebanese hospital isolates

Basma, R., Barada, G., Ojaimi, N. F. A., & Khalaf, R. A. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01559.x · Cited by 21

Investigation of the susceptibility of Candida species isolated from denture wearers to different antifungal antibiotics

Günyar, Ö. A., & Alev, H. U. (2011) · African Journal of Microbiology Research · doi:10.5897/ajmr10.693 · Cited by 20

Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance

Andes, D. R. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.06.002 · Cited by 19

Minimal Inhibitory Concentration (MIC)-Phenomena in Candida albicans and Their Impact on the Diagnosis of Antifungal Resistance

Binder, U., Aigner, M., Risslegger, B., Hörtnagl, C., Lass‐Flörl, C., & Lackner, M. (2019) · Journal of Fungi · doi:10.3390/jof5030083 · Cited by 22

Candida

Dignani, M. C., Solomkin, J. S., & Anaissie, E. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00008-6 · Cited by 19

The safety of anidulafungin

Vázquez, J. A. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.6.751 · Cited by 18

Mutants in the Candida glabrata Glycerol Channels Are Sensitized to Cell Wall Stress

Beese‐Sims, S. E., Pan, S., Lee, J., Hwang-Wong, E., Cormack, B. P., & Levin, D. E. (2012) · Eukaryotic Cell · doi:10.1128/ec.00231-12 · Cited by 17

Clinical utility of antifungal susceptibility testing

McCarty, T. P., Luethy, P. M., Baddley, J. W., & Pappas, P. G. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac067 · Cited by 17

Major Antifungal Drugs

Bell, A. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00216-9 · Cited by 16

Antifungal Resistance Testing and Implications for Management

Badali, H., & Wiederhold, N. P. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00354-6 · Cited by 16

Treatment of Candida albicans pericarditis in a heart transplant patient

Puius, Y. A., & Scully, B. E. (2007) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2006.00195.x · Cited by 16

Caspofungin

Garnock-Jones, K. P., & Keam, S. J. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911040-00005 · Cited by 15

Caspofungin Disk Diffusion Breakpoints and Quality Control

Brown, S. D., & Traczewski, M. M. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00279-08 · Cited by 15

Antifungal prophylaxis in the intensive care unit: Who should get it?*

Rex, J. H. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000208110.36504.19 · Cited by 15

Characterization of caspofungin susceptibilities by broth and agar inCandidaalbicansclinical isolates with characterized mechanisms of azole resistance

Silver, P. M., Silver, P. M., Oliver, B. G. G., & White, T. C. (2008) · Medical Mycology · doi:10.1080/13693780701816557 · Cited by 14

Candida Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms

Dominguez, E. G., & Andes, D. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_6 · Cited by 14

In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Perkhofer, S., Mrazek, C., Hartl, L., & Lass‐Flörl, C. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0134-z · Cited by 12

Gastrointestinal infections in the immunocompromised host

Mehta, S. J., & Fantry, L. E. (2005) · Current Opinion in Internal Medicine · doi:10.1097/00132980-200504000-00009 · Cited by 12

Susceptibilidad a azoles y anfotericina B de aislados de Candida spp: Experiencia de una red de salud universitaria,entre 2004 y 2010

Lorena Porte, T., León, P., Gárate, C., Guzmán, A. M., Labarca, J. A., & García, P. (2012) · Revista chilena de infectología · doi:10.4067/s0716-10182012000200005 · Cited by 11

Antifungal activity and potential mechanism of action of caspofungin in combination with ribavirin against Candida albicans

Wang, Y., Yan, H., Li, J., Zhang, Y., Wang, Z., & Sun, S. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106709 · Cited by 13

Utility of Antifungal Susceptibility Testing and Clinical Correlations

Diekema, D. J., & Pfaller, M. A. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5_8 · Cited by 9

Caspofungin therapy in immunocompromised children and neonates

Somer, A., Törün, S. H., & Salman, N. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.4 · Cited by 9

New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study

Rodríguez-Leguizamón, G., Fiori, A., Lagrou, K., Gaona, M. A., Ibáñez‐Pinilla, M., Patarroyo, M. A., Dijck, P. V., & Gómez-López, A. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0840-0 · Cited by 9

Antibacterial Resistance Patterns Among Common Infections in a Tertiary Care Hospital in Saudi Arabia

Hakami, A. Y., Felemban, L. H. A., Aljifri, N. A., Alyamani, G. M., Abosallamh, K. A., Aljohani, R., Aldosary, T. A., & Basheikh, A. (2022) · Cureus · doi:10.7759/cureus.31695 · Cited by 9

Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia

Lee, S.-C., Lee, C., Shih, H.-J., Huang, S.-H., Chiou, M., & See, L. (2013) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2013.09.006 · Cited by 8

Anidulafungin and its role in candida infections

Cappelletty, D. M. (2009) · Infection and Drug Resistance · doi:10.2147/idr.s4796 · Cited by 7

Impact of real-time fungal susceptibility on clinical practices

Magiorakos, A.-P., & Hadley, S. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00002 · Cited by 7

The Role of Resistance in Candida Infections: Epidemiology and Treatment

Sobel, J. D., & Akins, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_18 · Cited by 6

Approaches to Management of Invasive Fungal Infections in Patients with Hematologic Malignancies

Forrest, G. N., & Walsh, T. J. (2004) · Supportive Cancer Therapy · doi:10.3816/sct.2004.n.019 · Cited by 6

Successful Treatment of Recurrent Candidemia due to Candidal Thrombophlebitis Associated with a Central Venous Catheter Using a Combination of Fosfluconazole and Micafungin

Hagiya, H., & Kajioka, H. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0584 · Cited by 5

The Mechanisms of Resistance to Echinocandin Class of Antifungal Drugs

Niimi, K., & Niimi, M. (2009) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.50.057 · Cited by 6

Antifungal susceptibility profile and biofilm production of Candida spp. isolated from catheterised patients with urinary tract infection

Kamini, P., Thayanidhi, P., Karthika, K., & Bavadharani, S. (2022) · Journal of The Academy of Clinical Microbiologists · doi:10.4103/jacm.jacm_12_22 · Cited by 4

Caspofungin for the Treatment of Immunocompromised and Severely III Children and Neonates with Invasive Fungal Infections

Wiederhold, N. P., & Herrera, L. A. (2012) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s8016 · Cited by 6

Actividad in vitro de anidulafungina. Comparación con la actividad de otras equinocandinas

Martín‐Mazuelos, E., & Rodrı́guez-Tudela, J. L. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(08)76587-x · Cited by 4

Echinocandins

Groll, A. H., Schrey, D., & Walsh, T. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_6 · Cited by 4

Decreased susceptibility to viscosin in Streptococcus pneumoniae

Winther, A. R., Salehian, Z., Bøe, C. A., Nesdal, M., Håvarstein, L. S., Kjos, M., & Straume, D. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00624-24 · Cited by 3

ANTIFUNGAL RESISTANCE: A GROWING CONCERN

Firacative, C. (2023) · Acta Biológica Colombiana · doi:10.15446/abc.v28n3.104736 · Cited by 3

Caspofungin-resistant oral and esophageal candidiasis in a patient with AIDS

Jokela, J. A., & Kaur, P. (2006) · AIDS · doi:10.1097/qad.0b013e3280117f5f · Cited by 3

The Role of Resistance in Candida Infections: Epidemiology and Treatment

Sobel, J. D., & Akins, R. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_18 · Cited by 2

Candidiasis invasora en una paciente sometida a retrasplante unipulmonar

de Merlo-Martínez, P., Iranzo, R., & Fernandez, F. (2012) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.03.007 · Cited by 2

Gastric dilatation and perforation due to binge eating: a case report

Heijneman, J. A. M., Tahmassian, R., & Karsten, T. M. (2013) · Cited by 2

Glucan Synthase Inhibitors

Gumbo, T., Ikeda, F., & Louie, A. (2007) · Infectious disease and therapy · doi:10.3109/9781420017137.018 · Cited by 2

Inhibition of Fungal Biofilms

Pierce, C. G., Srinivasan, A., Uppuluri, P., Ramasubramanian, A. K., & Lopez-Ribot, J. L. (2014) · Springer series on biofilms · doi:10.1007/978-3-642-53833-9_13 · Cited by 1

Pharmacotherapy of Micafungin: Clinical Review

Riddell, J., & Kauffman, C. A. (2009) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s3412 · Cited by 1

Antifongigramme: techniques et interprétation

Paugam, A. (2005) · Bio Tribune Magazine · doi:10.1007/bf03013614 · Cited by 1

Echinocandins: Exploring Susceptibility and Resistance

Douglas, C. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_28 · Cited by 1

Diutina (Candida) rugosa complex: The biofilm ultrastructure, extracellular matrix, cell wall component and antifungal susceptibility to amphotericin B, caspofungin, fluconazole and voriconazolePreprint

Mahalingam, S. R. R., Madhavan, P., & Chong, P. P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.30.016246 · Cited by 1

[Effect of new antifungals on the etiology of invasive fungal infections: emergence, resistance and breakthrough infection].

Salavert, M., & Ramos, I. J. (2006) · PubMed · Cited by 1

Antifungal Drug Resistance: Clinical Importance, in vitro Detection and Implications for Prophylaxis and Treatment

Arthington, B. A., & Frade, J. P. (2010) · Issues in infectious diseases · doi:10.1159/000298761

Hijacking the Candida albicans Multidrug Resistant Transporter MDR1 to Potentiate Antifungal Activity

Sun, N. (2013) · DigitalGeorgetown (Georgetown University Library)

Mechanisms of azole resistance and carcinogenic acetaldehyde production in chronic mucosal candidosis

Siikala, E. (2011) · Työväentutkimus Vuosikirja

The Roles of Hsp90 and Calcineurin in Antifungal Drug Resistance

Singh, S. (2012) · TSpace (University of Toronto)

Development of the novel triazole antifungal, isavuconazole

山崎, 敏. (2014) · Terrestrial Environment Research Center (University of Tsukuba)

PREVALENCE OF VULVOVAGINAL CANDIDIASIS AMONG PRE AND POST-MENOPAUSAL DIABETIC AND NON-DIABETIC WOMEN

Savetha, P., Illamani, V., & Madhusudhanan, B. K. (2021) · Annals of the Romanian Society for Cell Biology

Management of Fungal Infections in Cancer Patients

Aoun, M., Klastersky, J. A., Buvé, K., & Maertens, J. A. (2008) · Translational medicine series · doi:10.3109/9781420052909.006

Acquired resistance to echinocandins in Candida albicans: case report and review

Baixench, M.-T., Aoun, N. B. T., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, É. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 149

Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin

Miller, C., Lomaestro, B. W., Park, S., & Perlin, D. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6.877 · Cited by 93

Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy

Hakki, M., Staab, J. F., & Marr, K. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00148-06 · Cited by 148

Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome

Kartsonis, N. A., Killar, J., Mixson, L. A., Hoe, C., Sable, C. A., Bartizal, K. F., & Motyl, M. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3616-3623.2005 · Cited by 138

Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans

Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-10 · Cited by 61